Canton Strategic Holdings (CNTN) Shares Outstanding (Weighted Average) (2020 - 2026)
Canton Strategic Holdings posted quarterly Shares Outstanding (Weighted Average) of $207.7 million for Q1 2026, up 41541081.0% year-on-year from N/an in Q1 2025, and up 359956.69% on a QoQ basis from $57687.0 in Q4 2025.
Canton Strategic Holdings (CNTN) has 7 years of Shares Outstanding (Weighted Average) data on file, last reported at $207.7 million in Q1 2026.
- For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 41541081.0% year-over-year to $207.7 million; the trailing twelve-month figure through Mar 2026 stood at $207.7 million (up 41541081.0% YoY), and the FY2025 full-year result was $57687.0, down 88.25% from the prior year.
- Shares Outstanding (Weighted Average) for Q1 2026 stood at $207.7 million, up from $57687.0 in the prior quarter.
- Across five years, Shares Outstanding (Weighted Average) topped out at $207.7 million in Q1 2026 and bottomed at $500.0 in Q1 2025.
- The 5-year median for Shares Outstanding (Weighted Average) is $187500.0 (2022), against an average of $13.3 million.
- The widest annual swing landed in 2025, when Shares Outstanding (Weighted Average) tumbled 99.94%; it then jumped 41541081.0% in 2026.
- A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $452686.0 in 2022, then slumped by 80.76% to $87079.0 in 2023, then jumped by 1388.64% to $1.3 million in 2024, then sank by 95.55% to $57687.0 in 2025, then jumped by 359956.69% to $207.7 million in 2026.
- The last three Shares Outstanding (Weighted Average) figures came in at $207.7 million (Q1 2026), $57687.0 (Q4 2025), and $274897.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 177,333.76 Bn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 185,491.37 Bn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 100.00 Bn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 55.66 Bn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 254.10 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 16.04 Bn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 104.00 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 132.89 Mn |
| 10 | Canton Strategic Holdings | 643.89 Mn | 602.36 Mn | - | 207.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 207.71 Mn |
| Dec 31, 2025 | 57,687.00 |
| Sep 30, 2025 | 274,897.00 |
| Jun 30, 2025 | 2.73 Mn |
| Mar 31, 2025 | 500.00 |
| Dec 31, 2024 | 1.30 Mn |
| Sep 30, 2024 | 263,248.00 |
| Jun 30, 2024 | 20,000.00 |
| Mar 31, 2024 | 885,683.00 |
| Dec 31, 2023 | 87,079.00 |
| Sep 30, 2023 | 187,500.00 |
| Jun 30, 2023 | 159,000.00 |
| Mar 31, 2023 | 187,500.00 |
| Dec 31, 2022 | 452,686.00 |
| Sep 30, 2022 | 187,500.00 |
| Jun 30, 2022 | 11.10 Mn |
| Mar 31, 2022 | 187,500.00 |
| Dec 31, 2021 | 6.36 Mn |
| Sep 30, 2021 | 6.36 Mn |
| Jun 30, 2021 | 6.36 Mn |
| Mar 31, 2021 | 6.36 Mn |
| Dec 31, 2020 | 6.35 Mn |